Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

CHRISTMAS… it’s THE ultimate eating challenge. But for the millions of us reportedly on weight loss jabs, what misery awaits?

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't taken ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...